Femasys Inc (FEMY) - Total Liabilities
Based on the latest financial reports, Femasys Inc (FEMY) has total liabilities worth $14.85 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Femasys Inc operating cash flow efficiency to assess how effectively this company generates cash.
Femasys Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Femasys Inc's total liabilities have evolved over time, based on quarterly financial data. Check Femasys Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Femasys Inc Competitors by Total Liabilities
The table below lists competitors of Femasys Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alcom Group Bhd
KLSE:2674
|
Malaysia | RM625.34 Million |
|
Peruvian Metals Corp
V:PER
|
Canada | CA$877.79K |
|
Hua Yang Bhd
KLSE:5062
|
Malaysia | RM374.52 Million |
|
Alla Public Company Limited
BK:ALLA
|
Thailand | ฿212.07 Million |
|
Klaria Pharma Holding AB
ST:KLAR
|
Sweden | Skr44.65 Million |
|
Renrenle Commercial Group Co Ltd
SHE:002336
|
China | CN¥2.06 Billion |
|
Arctic Gold Publ AB
ST:ARCT
|
Sweden | Skr8.58 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Femasys Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Femasys Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Femasys Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Femasys Inc (2019–2025)
The table below shows the annual total liabilities of Femasys Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $14.85 Million | +46.49% |
| 2024-12-31 | $10.14 Million | +7.84% |
| 2023-12-31 | $9.40 Million | +468.84% |
| 2022-12-31 | $1.65 Million | -26.34% |
| 2021-12-31 | $2.24 Million | -44.97% |
| 2020-12-31 | $4.08 Million | -92.97% |
| 2019-12-31 | $58.02 Million | -- |
About Femasys Inc
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornua… Read more